OpenAI acquires Orchestra Bio to accelerate drug development with AI
OpenAI acquires Orchestra Bio to integrate AI-powered operations into life sciences R&D, aiming to speed up drug development.
Drug development
Latest Drug development coverage.
Biossil hits $1B valuation after OpenAI-led $153M round to revive failed drugs
Biossil raises $153M led by OpenAI to resurrect abandoned drug candidates using AI, hitting $1B valuation.
Claude's 35% hit rate reshapes protein design, slashes drug development time
Anthropic's Claude achieves 35% hit rate in protein design, outperforming human experts and accelerating drug development.
Anthropic's $50,000 AI grants target rare disease research
Anthropic offers $50,000 in AI credits to researchers tackling rare genetic diseases through its AI for Science program.